Lates News

Each AI Express, on August 30, Open Source Securities released a research report giving a buy rating to Haweiyuan Medicine (688131.SH). The main reasons for the rating include: 1) The company's performance in 2025H1 continues to exceed expectations, with stable development of both front and back-end businesses; 2) The front-end life science reagent business is growing strongly, with continued improvement in profitability; 3) The back-end business has seen a steady growth in order amounts, with the CDMO business chain continuing to extend. (Daily Economic News)